DRUG

DRUG

Bright Minds Biosciences Inc

Rev โ€”top 1%5Y
Hold

Bright Minds Biosciences Inc. develops therapeutics targeting severe neurological conditions, focusing on 5-HT2 receptor agonists for epilepsy and neuropsychiatric disorders. Its pipeline includes drugs in clinical trials for various epilepsy types and Prader-Willi Syndrome.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ CAD
$1,000 invested 5 years ago โ†’$3,100today

Score Overview

1 Year
Scoreโ€”
Net Growth-62.27%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-133.04%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-133.04%
Net Trend40%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Bright Minds Biosciences Inc fundamental performance

Across Bright Minds Biosciences Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 8M to -$ 12M. Revenue increased in 0% of the years measured; net income in 40%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 79.37โ€”
1 Year2025-08-12
$ 39.49100.99%
5 Years2021-08-12
$ 25.60210.04%
All Time2021-03-22
$ 27.00193.96%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 19M$ 89M
2025$ 0.00-$ 12M$ 82M
2024$ 0.00-$ 2M$ 5M
2023$ 0.00-$ 7M$ 6M
2022$ 0.00-$ 14M$ 11M
IPO2021$ 0.00-$ 8M$ 19M

Explore beyond DRUG

You're looking at Bright Minds Biosciences Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies